CASP3 and prostate cancer: Other relevant in vivo results include: inhibition of serum prostate cancer marker PSA; activation of DNA damage-related protein PARP; activation of mitochondrial pathway of apoptosis, with increase in the levels of pro-apototic protein BAX, decrease in the levels of anti-apoptotic protein BCL-2 and activation of caspases -3, -8 and -9, inhibition of cell proliferation markers (Ki-67 and PCNA) and angiogenesis markers (CD31 and VEGF).